Evidence map›Paper›PMID 36708378›Full record

ArticleWorld journal of urology2023

Emergency holmium laser enucleation of the prostate (HoLEP): a novel approach in the management of refractory hematuria for patients with benign prostatic hyperplasia (BPH): a single-institution experience.

Hazem Elmansy, Amr Hodhod, Moustafa Fathy, Philippe D Violette, Ahmed Elshafei, Ahmed S Zakaria, Ryan Kelly, Radu Rozenberg, Amer Alaref, Loay Abbas and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Hazem ElmansyUrology Department, Northern Ontario School of Medicine, 146 Court Street South, Thunder Bay, ON, P7B 2X6, Canada. hazem.mansy@rocketmail.com.ORCID http://orcid.org/0000-0003-3601-4626
Amr HodhodUrology Department, Northern Ontario School of Medicine, 146 Court Street South, Thunder Bay, ON, P7B 2X6, Canada.
Moustafa FathyUrology Department, Northern Ontario School of Medicine, 146 Court Street South, Thunder Bay, ON, P7B 2X6, Canada.
Philippe D VioletteDepartments of Surgery and Health Research Methods Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Ahmed ElshafeiUrology Department, Northern Ontario School of Medicine, 146 Court Street South, Thunder Bay, ON, P7B 2X6, Canada.
Ahmed S ZakariaUrology Department, Northern Ontario School of Medicine, 146 Court Street South, Thunder Bay, ON, P7B 2X6, Canada.
Ryan KellyUrology Department, Northern Ontario School of Medicine, 146 Court Street South, Thunder Bay, ON, P7B 2X6, Canada.
Radu RozenbergRadiology Department, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Amer AlarefRadiology Department, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Loay AbbasUrology Department, Northern Ontario School of Medicine, 146 Court Street South, Thunder Bay, ON, P7B 2X6, Canada.
Ruba Abdul HadiUrology Department, Northern Ontario School of Medicine, 146 Court Street South, Thunder Bay, ON, P7B 2X6, Canada.
Ahmed KotbUrology Department, Northern Ontario School of Medicine, 146 Court Street South, Thunder Bay, ON, P7B 2X6, Canada.
Walid ShahrourUrology Department, Northern Ontario School of Medicine, 146 Court Street South, Thunder Bay, ON, P7B 2X6, Canada.
NOSM University · CAImpact · CAMenoufia University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRefractory hematuria secondary to prostatic disease typically resolves with conservative management; however, this condition may require hospitalization with extensive measures to control life-threatening bleeding. The aim of this study was to report our experience using holmium laser enucleation of the prostate (HoLEP) as an emergency treatment in this clinical setting.

methodsWe conducted a retrospective review of all patients that presented to the emergency department with refractory hematuria of prostatic origin from October 2017 to September 2021, for whom hospitalization and conservative management failed to control bleeding. All emergency HoLEP procedures were performed by a single surgeon. Preoperative and intraoperative parameters, as well as perioperative outcomes, were collected and analyzed. Postoperative outcomes included duration of foley catheterization, length of postoperative hospital stay, and hospital readmissions.

resultsA total of 40 emergency HoLEP procedures were performed. Our cohort had a median prostate volume of 110.5 cc and a median resected weight of 81 g. Twenty-seven patients (67.5%) were on anticoagulant or antiplatelet medications on admission. The urethral catheter was removed within 1 day in 95% of patients with a successful trial of void (TOV). Moreover, 92.5% of patients were discharged home within 24 h of their procedure. Two patients (5%) experienced clot retention within one-week post-discharge with a 2.5% overall readmission rate. All postoperative parameters, including International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax), and post-void residual volume (PVR), showed significant improvement at 1 year follow up.

conclusionOur experience demonstrates that emergency HoLEP is an effective treatment option for patients with refractory hematuria of prostatic origin. Further studies are warranted to consolidate our results.

Indexed as

Lasers, Solid-StateLaser TherapyProstatic HyperplasiaTransurethral Resection of ProstateAftercareHematuriaHolmiumHumansMalePatient DischargeProstateQuality of LifeRetrospective StudiesTreatment OutcomeHolmiumBenign prostatic hyperplasiaEnucleationLaser

Identifiers

PMID36708378
OpenAlexW4318391538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.